Form 4: Oruka CMO Sells Shares, Exercises Options

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, reported exercising stock options and warrants while selling common stock, including shares under a 10b5-1 plan and for tax obligations.

Summary

• Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, Inc. (ORKA), reported multiple transactions on March 16, 2026.
• Exercised employee stock options to acquire 3,500 shares of common stock at an exercise price of $6.84 per share.
• Exercised employee warrants to acquire 3,500 shares of common stock at an exercise price of $7.8 per share.
• Sold a total of 7,000 shares of common stock under a Rule 10b5-1 trading plan, with weighted average prices ranging from $40.1091 to $41.9361.
• Sold an additional 641 shares of common stock at $41.3 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Joana Goncalves beneficially owns 33,377 shares of common stock directly.
• Remaining derivative securities include 214,563 employee stock options and 185,992 employee warrants.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executives managing their equity compensation, involving both option exercises and sales for diversification and tax purposes. It does not provide new fundamental insights into the company's operational performance or strategic direction.

Positives

• The exercise of employee stock options and warrants indicates the executive is realizing value from their equity compensation, with exercise prices significantly below the market sale prices.
• The option and warrant vesting schedules (1/4 on April 18, 2025, then monthly) provide a long-term incentive for the executive.

Negatives

• Significant sales of common stock by a Chief Medical Officer could be interpreted by some investors as a reduction in direct exposure to the company's equity.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported in a Form 4, are routinely monitored by investors for insights into management's perspective on the company's stock. While sales can sometimes raise concerns, transactions executed under a pre-arranged 10b5-1 trading plan are generally viewed as less indicative of a change in sentiment, as they are scheduled in advance and not based on new, non-public information. Sales for tax withholding are also common practice for executives managing equity compensation.

Stakeholder Impact

• Shareholders may observe the executive's equity management, which includes both realizing gains from options/warrants and selling shares. The sales under a 10b5-1 plan and for tax obligations are generally considered routine and less impactful than discretionary sales.

Next Steps

• Ongoing vesting of remaining employee stock options and warrants from April 18, 2025, onwards.

Key Dates

Recommendation

The transactions represent routine management of equity compensation, including exercising options and selling shares for diversification and tax purposes. While there are sales, they are partially offset by option exercises and conducted under a pre-arranged 10b5-1 plan, which typically mitigates concerns about opportunistic selling. There is no new fundamental information about the company's operations or prospects to warrant a change in investment stance.

Keywords

Oruka Therapeutics, ORKA, Form 4, Insider Trading, Stock Options, Stock Sales, 10b5-1 Plan, Chief Medical Officer, Joana Goncalves, Equity Compensation